Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
Jian LiShirong CaiYongjian ZhouJun ZhangYe ZhouHui CaoXin WuYanhong DengZhao HuangJuan DongLin ShenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The results demonstrated that ripretinib can clinically improve the outcomes of Chinese patients with advanced GIST as a fourth- or later-line therapy. The efficacy, safety, and PK profiles of ripretinib are consistent with those in the global patient population.